Txcell (PA:TXCL) has announced it has a promising humanised CAR-Treg product that can be developed to control graft rejection in solid organ transplant. A trial is planned to start in late 2018. CAR Tregs offer a powerful and versatile new approach to immune system disorders; multiple sclerosis, lupus nephritis and the skin disorder bullous pemphigoid are also targets. TxCell had cash of €8.68m on 30 June. The indicative market cap has been rebased onto CAR Treg indications and is now €84.4m, formerly €74m.
Focus on CAR Treg with four preclinical projects
TxCell is clearly set on being the leading CAR Treg company based on ENTrIA technology development. The ENTrIA platform uses chimeric antigen receptor (CAR) technology similar to that in the CAR T-cell cancer area. Developing a humanised CAR Treg is an important step as long-term control of chronic diseases may need repeat dosing. A granted European patent (licensed globally in June 2016) offers broad protection. CAR Treg trials are planned from late 2018 with solid organ transplant rejection as a lead indication. This is based on an academic collaboration and new humanised CAR Treg. Other indications are lupus nephritis, bullous pemphigoid (skin) and multiple sclerosis. We expect ENTrIA to be an excellent basis for partnering and technology licensing.
To read the entire report Please click on the pdf File Below: